Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Liquidia Technologies ( (LQDA) ) is now available.
Liquidia Corporation reported that in the first quarter of 2026, its inhaled PAH drug YUTREPIA generated about $130 million in net product sales, supporting net income of $52.9 million and adjusted EBITDA of $71.2 million, marking a third straight profitable quarter. Since YUTREPIA’s June 2025 U.S. launch, more than 4,500 unique prescriptions have been written, roughly 3,750 patients have started therapy with a conversion rate of at least 85%, and the company has expanded its prescriber base while investing in Phase 4 studies of YUTREPIA and the pivotal Phase 3 Re-Spire trial of L606, strengthening its position in the PAH and PH-ILD markets.
As of March 31, 2026, cash and cash equivalents rose to $222.8 million, supported by strong YUTREPIA uptake that offset higher research and development and selling, general and administrative expenses tied to clinical programs and commercialization. The shift from a $38.4 million net loss a year earlier to meaningful profitability underscores a major financial inflection for Liquidia, with growing recurring revenue from PAH and PH-ILD therapies expected to underpin continued investment in its pulmonary hypertension portfolio and potentially reshape competition in the inhaled prostacyclin segment.
The most recent analyst rating on (LQDA) stock is a Buy with a $54.00 price target. To see the full list of analyst forecasts on Liquidia Technologies stock, see the LQDA Stock Forecast page.
Spark’s Take on LQDA Stock
According to Spark, TipRanks’ AI Analyst, LQDA is a Neutral.
Overall score reflects high financial risk (losses, elevated leverage, and weak cash-flow visibility in the financial statements) despite strong and improving commercial execution highlighted on the earnings call. Technicals are neutral-to-soft and valuation support is limited due to a negative P/E and no dividend yield provided.
To see Spark’s full report on LQDA stock, click here.
More about Liquidia Technologies
Liquidia Corporation is a U.S.-based biopharmaceutical company focused on treating challenging respiratory and vascular diseases, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its lead products include YUTREPIA, an inhaled dry-powder treprostinil, and a generic Treprostinil Injection promoted with Sandoz, alongside the investigational liposomal inhalation therapy L606.
Average Trading Volume: 1,383,907
Technical Sentiment Signal: Buy
Current Market Cap: $3.73B
For detailed information about LQDA stock, go to TipRanks’ Stock Analysis page.